Ruxolitinib in Myelofibrosis and Polycythemia Vera.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

7 citing papers in PubMed.

1. Selective Inhibitors of Janus Kinase 3 Modify Responses to Lipopolysaccharides by Increasing the Interleukin-10-to-Tumor Necrosis Factor α Ratio.ACS pharmacology & translational science · 2023
   Article
2. The development of COVID-19 treatment.Frontiers in immunology · 2023
   Review
3. Pharmacokinetic Optimization of Small Molecule Janus Kinase 3 Inhibitors to Target Immune Cells.ACS pharmacology & translational science · 2022
   Article
4. Binding of the small-molecule kinase inhibitor ruxolitinib to membranes does not disturb membrane integrity.Biochemistry and biophysics reports · 2020
   Article
5. Efficacy of JAK inhibitors in Crohn's Disease.Journal of Crohn's & colitis · 2020
   Review
6. Block-And-Lock Strategies to Cure HIV Infection.Viruses · 2020
   Review
7. Hi-Frontiers in medicine · 2020
   Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.